Biogen Inc vs Wayfair Inc — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while Wayfair Inc trades at $104.76 (market cap $14.14B). The key difference: Biogen Inc is far larger — about 2.1× Wayfair Inc's market cap. Which is the better fit depends on your goals.
| BIIB | W | |
|---|---|---|
Market Cap | $30.13B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $119.05 |
52-Week Low | $128.93 | $57.40 |
Enterprise Value | $37.20B | $16.47B |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →